AstraZeneca beats expectations

AstraZeneca reported first-quarter results that significantly exceeded market expectations, fueled by a surge in demand for its oncology portfolio.

The company's blockbuster cancer treatments, including Tagrisso and Imfinzi, drove a double-digit increase in total revenue.

Alongside the earnings beat, AstraZeneca announced a new £300 million investment in its U.K. manufacturing and R&D facilities.

CFO Aradhana Sarin stated that 2026 is shaping up to be another 'catalyst-rich' year for the pharmaceutical giant as it advances several late-stage clinical trials.